DCTH (Delcath Corp) Earnings per share growth rate in current year
The percentage deviation of EPS from last year demonstrates volatility while the indicator stands at -31.70. Delcath Systems, Inc. (DCTH) ensures flexibility by outsourcing production and testing to external partners. Fundamentally, growth depends on management's ability to implement the organ isolation system in clinics. Meanwhile, Delcath Systems, Inc. (DCTH) minimizes environmental impact by adhering to standard laboratory ecological norms.
Financial and market metric breakdowns for Delcath Systems, Inc. (DCTH)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Debt to Equity Delcath Systems, Inc.|DCTH - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio delcath.com|DCTH - Company Aggregate Debts|Debts to Book Capitalization Delcath Corp|DCTH - Company Long-Term Liabilities|Amount of Current Liabilities Delcath Systems|Intermediate Coverage Ratio delcath.com
- earnings and market ratios statistics:
DCTH - Net Income|Expected Net Income Delcath Systems, Inc.|DCTH - Price to Earnings Ratio|Market Cap to Projected Earnings Delcath Corp|DCTH - Price/Earnings to Growth Multiple|Company Value to EBITDA Delcath Corp|DCTH - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Delcath Systems|DCTH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months delcath.com|DCTH - Earnings growth in current year|Expected net earnings per share growth next year Delcath Systems, Inc.
Fundamental valuation:Delcath Systems, Inc.
Conservative capital requires transparent profit dynamics to confirm business sustainability. This indicator measures the annual change in net income per share, allowing for an assessment of monetization efficiency and the company's ability to overcome inflationary pressure. Thanks to absolute pricing power and inelastic demand for the HEPZATO system, the EPS YoY trend clearly demonstrates the market dominance of Delcath Systems, Inc. (DCTH).
Key competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Earnings growth in current year AAPG|cgoncology.com - Earnings per share growth this year|Earnings growth in current year URGN (UroGen Pharma)|Bicara Therapeutics Inc (BCAX) - Earnings per share growth rate in current year|PSNL - Earnings per share growth in current year|ERAS: Earnings per share growth in current year|YMAB: Earnings growth in current year|Net earnings per share growth this year aurabiosciences.com|CADL (Candel Therapeutics Inc.) - Earnings growth in current year|Earnings growth in current year Accuray Inc|Net earnings per share growth this year SLS (SELLAS Life Sciences)|Net earnings per one share growth for the current year ACTU|Earnings growth in current year CTOR (Citius Oncology, Inc.)|Earnings per share increase in current year HURA|TARA: Net earnings per share growth this year|Earnings per share increase in current year FATE (Fate Therapeutics Inc)|aadibio.com (WHWK) - Earnings per share growth in current year|TCRX - Expected net earnings per share growth this year|Net earnings per share growth this year CSBR|Earnings per share growth rate in current year XBiotech USA XBIT|Earnings per share growth in current year CEL-SCI Corporation (CVM)|Expected net earnings per share growth this year OS Therapies Inc.|Radiopharm Theranostics - Net earnings per share growth this year|Net earnings per one share growth for the current year ARTV (Artiva Biotherapeutics Inc.)|Adlai Nortye Limited - Earnings growth in current year|Earnings per share growth rate in current year verupharma.com|Tempest Therapeutics, Inc. (TPST) - Earnings per share growth in current year|Net earnings per share growth this year Xilio Therapeutics|Earnings per share growth in current year Renovaro Biosciences|Mural Bio (MURA) - Expected net earnings per share growth this year|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|OKUR (onkuretherapeutics.com) - Earnings per share increase in current year|Earnings growth in current year GDTC (CytoMed Therapeutics Limited)|Expected net earnings per share growth this year Curis Inc. (CRIS)|APLM - Earnings per share growth in current year|THAR (Tharimmune Corporation) - Earnings per share growth this year|ADVB: Earnings growth in current year|Net earnings per share growth this year genprex.com|Net earnings per share growth this year CLDI|sunshinebiopharma.com (SBFM) - Expected net earnings per share growth this year|Earnings growth in current year XBIO|Salarius Pharma - Earnings per share growth this year|Earnings growth in current year PPBT (Purple Biotech)|AONC - Net earnings per share growth this year|BGNE: Net earnings per share growth this year|Checkpoint Therapeutics Inc. - Net earnings per one share growth for the current year|ELEV: Earnings growth in current year|iCAD - Earnings per share increase in current year|IKNA (Ikena Oncology Inc.) - Earnings growth in current year|Net earnings per share growth this year notablelabs.com (NTBL)|Earnings growth in current year VIRX|Earnings growth in current year MorphoSys Inc (MOR)|Earnings per share growth in current year NAYA Bio NAYA|AAPGV: Earnings per share growth this year
